Authors:
Gaspar, LE
Winter, K
Kocha, WI
Pinover, WH
Herskovic, A
Graham, M
Gunderson, L
Citation: Le. Gaspar et al., Swallowing function and weight change observed in a phase I/II study of external-beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 9207), CANCER J, 7(5), 2001, pp. 388-394
Authors:
Pingpank, JF
Hoffman, JP
Ross, EA
Cooper, HS
Meropol, NJ
Freedman, G
Pinover, WH
LeVoyer, TE
Sasson, AR
Eisenberg, BL
Citation: Jf. Pingpank et al., Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas, J GASTRO S, 5(2), 2001, pp. 121-130
Authors:
Winter, DL
Hanlon, AL
Raysor, SL
Watkins-Bruner, D
Pinover, WH
Hanks, GE
Tricoli, JV
Citation: Dl. Winter et al., Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer, UROLOGY, 58(4), 2001, pp. 614-618
Citation: Em. Horwitz et al., Re: Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques, J UROL, 165(4), 2001, pp. 1224-1224
Authors:
Horwitz, EM
Hanlon, AL
Pinover, WH
Anderson, PR
Hanks, GE
Citation: Em. Horwitz et al., Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques, CANCER, 92(5), 2001, pp. 1281-1287
Authors:
Pinover, WH
Hanlon, AL
Horwiltz, EM
Hanks, GE
Citation: Wh. Pinover et al., Defining the appropriate radiation dose for pretreatment PSA <= 10 ng/mL prostate cancer, INT J RAD O, 47(3), 2000, pp. 649-654
Authors:
Hanks, GE
Hanlon, AL
Pinover, WH
Horwitz, EM
Price, RA
Schultheiss, T
Citation: Ge. Hanks et al., Dose selection for prostate cancer patients based on dose comparison and dose response studies, INT J RAD O, 46(4), 2000, pp. 823-832
Authors:
Movsas, B
Chapman, JD
Greenberg, RE
Hanlon, AL
Horwitz, EM
Pinover, WH
Stobbe, C
Hanks, GE
Citation: B. Movsas et al., Increasing levels of hypoxia in prostate carcinoma correlate significantlywith increasing clinical stage and patient age - An Eppendorf pO(2) study, CANCER, 89(9), 2000, pp. 2018-2024
Authors:
Hanks, GE
Hanlon, AL
Pinover, WH
Horwitz, EM
Schultheiss, TE
Citation: Ge. Hanks et al., Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy, CA J SCI AM, 5(3), 1999, pp. 152-158
Authors:
Horwitz, EM
Hanlon, AL
Pinover, WH
Hanks, GE
Citation: Em. Horwitz et al., Is there a role for short-term hormone use in the treatment of nonmetastatic prostate cancer?, RADIAT ON I, 7(4), 1999, pp. 249-259
Authors:
Algan, O
Pinover, WH
Hanlon, AL
Al-Saleem, TI
Hanks, GE
Citation: O. Algan et al., Is there a subset of patients with PSA >= 20 ng/ml who do well after conformal beam radiotherapy?, RADIAT ON I, 7(2), 1999, pp. 106-110
Authors:
Horwitz, EM
Hanlon, AL
Pinover, WH
Hanks, GE
Citation: Em. Horwitz et al., The cost effectiveness of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer, INT J RAD O, 45(5), 1999, pp. 1219-1225
Authors:
Tricoli, JV
Winter, DL
Hanlon, AL
Raysor, SL
Watkins-Bruner, D
Pinover, WH
Hanks, GE
Citation: Jv. Tricoli et al., Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer, UROLOGY, 54(1), 1999, pp. 178-182
Authors:
Iyer, RV
Hanlon, AL
Pinover, WH
Hanks, GE
Citation: Rv. Iyer et al., Outcome evaluation of the 1997 American Joint Committee on Cancer staging system for prostate carcinoma treated by radiation therapy, CANCER, 85(8), 1999, pp. 1816-1821